Inve India ▾

Sanofi India share price & results

Sanofi India Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Indian arm of Sanofi, leading in insulin-led diabetes care plus cardiovascular, CNS and anti-infective brands.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue438 ₹ crore+7.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin26.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit84.0 ₹ crore+20.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equityUnavailable−10.9 ptsFY Dec 2024 vs FY Dec 2023Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow marginUnavailable+10.2 ptsFY Dec 2024 vs FY Dec 2023Fiscal yearFY · period unavailableNot in the analysed materials. No older figure is substituted.
Revenue growth (YoY)Unavailable—Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 5 judged targets kept · 6 open · verdicts reflect calls analysed to Q1 FY27.

Sanofi India Limited management guidance track record on Inve: 11 targets tracked across analysed earnings calls (3 achieved, 2 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
Personnel Costsaving will be more and more in the personnel cost next year
Call transcript, Q2 FY26 · 29 Oct 2025		Q2 FY26Q1 FY27:The trend of cost control continues, with overall operating expenses down 5% in Q2 and 15% in H1 2026, reinforcing the achievement of this promise.
Call transcript, Q1 FY27 · 5 Aug 2026		Achieved
Digital TransformationEnd of this year, we will be aligned to the more modern system that we have within the group in India.
Call transcript, Q2 FY26 · 29 Oct 2025		Q2 FY26Q1 FY27:The end-of-2025 deadline has passed with no confirmation of completion. Vague mentions of evaluating 'AI platforms' do not satisfy the specific promise of alignment with the group's system.
Call transcript, Q1 FY27 · 5 Aug 2026		Missed
Partnership Segment Growthwe are growing by 2% in this segment and we are aiming to continue to grow that
Call transcript, Q2 FY26 · 29 Oct 2025		Q2 FY26Q1 FY27:The business returned to 2% growth in Q2 2026. However, management does not expect to reach industry growth in 2026, placing the sustainability of this growth at risk.
Call transcript, Q1 FY27 · 5 Aug 2026		At Risk

Source: Inve Guidance Tracker for Sanofi India Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Sanofi India Limited's 11 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 8 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,852.8 +2.89% · +₹80

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −39.5% 1Y

₹3.0k₹3.5k₹4.0k₹4.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 29 Oct 2025Q3 FY26 — 26 Feb 2026Q1 FY27 — 5 Aug 2026

1Y: ₹4,712.2 on 24 Oct 2025 → ₹2,852.8. High ₹4,807.1 (30 Oct 2025), low ₹2,772.8 (23 Oct 2026).

Previous close
₹2,772.8
Market cap
₹6.6k Cr
52-week range
₹2,772.8 – ₹4,807.1
One year
−39.23%

Overview

Symbol
NSE:SANOFI
Exchange
NSE
Currency
INR

What Sanofi India Limited does

Based on the company's own presentations, annual report and earnings calls.

Sanofi India Limited is the Indian listed subsidiary of French pharma major Sanofi S.A. (together with Hoechst GmbH holding 60.40% of shares), manufacturing and marketing prescription medicines across diabetes, cardiovascular, central nervous system (CNS) and anti-infective therapies. Its diabetes franchise is anchored by the insulin brands Lantus, Toujeo and Soliqua, while its legacy CV/CNS/anti-infective portfolio is increasingly distributed through a partnership model with third parties. Products are made at its own GMP-compliant plant in Goa and supplied via a network of roughly 2,900 distributors reaching hospitals, retail chains and healthcare institutions across India, with additional volumes exported to 25 countries and supplemented by seven Indian contract manufacturing organisations.

Segments

  • Diabetes
  • Cardiovascular
  • Central Nervous System (CNS)
  • Anti-Infectives
Manufacturing facility
1 GMP-compliant plant (Goa)
Annual production capacity
5 billion units of oral solid dosage forms
Export markets
25 countries
Contract manufacturing partners
7 Indian CMOs
Distributor network
2,900 distributors
Workforce
1,104 (including contractual employees and workers)
Founded 1956Headquarters Sanofi House, Saki Vihar Road, Powai, Mumbai 400072 Company website

How the price took the results

close before → close after

Q1 FY27
−1.9%
5 Aug
Q3 FY26
−2.9%
26 Feb
Q2 FY26
−0.4%
29 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sanofi India Limited

Free account: one company. Everything above stays public.

Write why you follow Sanofi India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sanofi India Limited

Guides on how to read this kind of business and the numbers that matter.